文献速递银屑病与炎症性皮肤病

Ixekizumab改善中重度银屑病患者的指甲银屑病:UNCOVER-3随机对照及开放标签期结果

Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3.
PubMed 文献 · J Eur Acad Dermatol Venereol · 2016-12-02

UNCOVER-3试验的亚组分析纳入基线有指甲银屑病的患者,评估ixekizumab对指甲银屑病的疗效。第12周时,ixekizumab每4周和每2周组的NAPSI平均改善百分比均显著优于安慰剂和依那西普;第60周时,无论初始治疗如何,NAPSI平均改善均超过80%。

要点

  • 第12周,ixekizumab每4周和每2周组NAPSI平均改善百分比显著优于安慰剂和依那西普。
  • 第12周,ixekizumab组完全缓解(NAPSI=0)比例显著高于安慰剂和依那西普。
  • 第60周,超过50%的患者达到完全缓解。

核心结论

  • 第12周时,ixekizumab治疗显著改善指甲银屑病。
  • 采用IXE Q4W维持 dosing,至60周时显示额外改善,超过50%的患者达到完全缓解。

研究设计与样本

  • UNCOVER-3是一项3期双盲试验,患者随机接受安慰剂、依那西普(50 mg每周两次)或ixekizumab(起始160 mg后,每4周或每2周80 mg)。
  • 第12周后,ixekizumab组患者接受开放标签IXE Q4W至第60周;安慰剂组接受ixekizumab起始160 mg后IXE Q4W;依那西普组经过4周安慰剂洗脱后开始IXE Q4W。
  • 本亚组分析仅纳入基线有指甲银屑病的患者:安慰剂组116例(60.1%),依那西普组236例(61.8%),IXE Q4W组228例(59.1%),IXE Q2W组229例(59.5%)。

主要发现

  • 第12周,IXE Q4W组NAPSI平均改善百分比为36.7%,IXE Q2W组为35.2%,安慰剂组为-34.3%(每项比较P < 0.001),依那西普组为20.0%(vs Q4W P = 0.048,vs Q2W P = 0.072)。
  • 第60周,无论初始治疗如何,NAPSI平均改善百分比均超过80%。
  • 第12周(无应答者填补),完全缓解(NAPSI = 0)比例:IXE Q4W组19.7%,IXE Q2W组17.5%,安慰剂组4.3%(每项比较P < 0.001),依那西普组10.2%(每项比较P < 0.05)。
  • 至第60周,超过50%的患者达到完全缓解。

临床怎么用

  • 对于中重度银屑病合并指甲受累的患者,ixekizumab可显著改善指甲银屑病。
  • 长期维持治疗可进一步提高指甲银屑病的完全缓解率。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Fingernail psoriasis is difficult to treat. OBJECTIVE: The objective was to evaluate the effect of ixekizumab, a monoclonal antibody selectively targeting IL-17A, on fingernail psoriasis. METHODS: This Phase 3, double-blind trial (UNCOVER-3) randomized patients to placebo, etanercept (50-mg twice weekly), or 80 mg ixekizumab as one injection every 4 (IXE Q4W) or 2 weeks (IXE Q2W) after a 160-mg starting dose. At Week 12, ixekizumab patients received open-label IXE Q4W through Week 60; placebo patients received a 160-mg starting ixekizumab dose and etanercept patients a 4-week placebo washout before starting IXE Q4W. Efficacy was assessed by mean per cent Nail Psoriasis Severity Index (NAPSI) improvement at Weeks 12 and 60. RESULTS: Of 1346 patients in the UNCOVER-3 trial, this subgroup analysis included only patients with baseline fingernail psoriasis: 116 (60.1%) placebo, 236 (61.8%) etanercept, 228 (59.1%) IXE Q4W and 229 (59.5%) IXE Q2W. At Week 12, greater mean per cent NAPSI improvements were achieved in IXE Q4W (36.7%) and IXE Q2W (35.2%) vs. placebo (-34.3%, P < 0.001 each comparison) and etanercept (20.0%, P = 0.048 vs. Q4W, P = 0.072 vs. Q2W). At Week 60, mean per cent NAPSI improvement was >80% regardless of initial treatment. At Week 12 (nonresponder imputation), complete resolution (NAPSI = 0) was achieved in 19.7% (IXE Q4W), 17.5% (IXE Q2W), 4.3% (placebo, P < 0.001 each comparison) and 10.2% (etanercept, P < 0.05 each comparison) of patients. By Week 60, >50% of patients achieved complete resolution. CONCLUSIONS: At Week 12, significant improvements in fingernail psoriasis were achieved with ixekizumab therapy. With IXE Q4W maintenance dosing, additional improvement was demonstrated through 60 weeks, and >50% of patients achieved complete resolution. Registered at clinicaltrials.gov: NCT01646177.

来源:J Eur Acad Dermatol Venereol,查看原文。版权归原作者所有。

引用

  1. van de Kerkhof P, Guenther L, Gottlieb AB, et al. Ixekizumab treatment improves fingernail psoriasis in patients with moderate-to-severe psoriasis: results from the randomized, controlled and open-label phases of UNCOVER-3. J Eur Acad Dermatol Venereol. 2016. PMID: 27910156. doi:10.1111/jdv.14033

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。